Mansour Nejadrasool, DPM
Foot Surgery · van Nuys, CANPI 1477565828
Payments from drug & device makers
What this record shows
18 manufacturers reported payments, led by Treace Medical Concepts, Inc. at 56.8% of the total. Reporting peaked in 2022 at $946 and has fallen 76.5% since, to $222 in 2025.
Across 28 payments — averaging $57.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Treace Medical Concepts, Inc.$907
- Vertex$165
- Zimmer Biomet$66
- Stryker$57
- Smith+Nephew$47
- Paratek Pharmaceuticals, Inc.$47
- plus $309 from 12 others
What the payments were for
- Travel & lodging$90156%
- Food & beverage$69744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Treace Medical Concepts, Inc. | 3 | $907 |
| Vertex | 5 | $165 |
| Zimmer Biomet | 3 | $66 |
| Stryker | 1 | $57 |
| Smith+Nephew | 1 | $47 |
| Paratek Pharmaceuticals, Inc. | 2 | $47 |
| Mimedx Group, Inc. | 2 | $45 |
| Orthofix Medical, Inc. | 1 | $41 |
| Bone Support Inc. | 1 | $34 |
| Medtronic | 1 | $33 |
| Biotissue Holdings Inc. | 1 | $25 |
| GRT US Holding, Inc. | 1 | $24 |
| Paragon 28, Inc. | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Linvatec Corporation | 1 | $18 |
| Integra Lifesciences Corporation | 1 | $18 |
| Organogenesis Inc. | 1 | $17 |
| Heron Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,597 in reported general payments places this provider in the 70th percentile of 71 foot surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 37 | $207 |
| Doxycycline Monohydrate | 14 | $137 |
| Naproxen | 28 | $102 |
| Tramadol Hcl | 14 | $29 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in van Nuys
- Alexander ReyzelmanSan Francisco$137K
- Helen ShnolBeverly Hills$22K
- Benedict ChingFountain Valley$19K
- Zachary KramerEncinitas$14K
- Tara HarringtonElk Grove$12K
- Jack MorganMonterey Park$11K
- Jaehyun KimSunnyvale$7K
- Ingrid EdelmanSan Diego$6K
- Spencer SterlingBellflower$5K
- Beverly SpursConcord$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.